Kindred Biosciences is a veterinary biopharmaceutical company focused on saving and improving the lives of cats, dogs, and horses. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for animal companions. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.
Location: United States, California, Burlingame
Employees: 51-200
Total raised: $50M
Founded date: 2012
Investors 1
| Date | Name | Website |
| - | EcoR1 Capi... | ecor1cap.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.10.2019 | - | $50M | - |
Mentions in press and media 16
| Date | Title | Description |
| 08.03.2024 | DEADLINE ALERT for PANW, PLCE, SNOW, and KIND: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders | - |
| 17.06.2021 | The return of former Athenahealth CEO, Jonathan Bush | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content Why the Electricity 4.0 moment is here From Schneider Electric Almost three years ag... |
| 17.06.2021 | The return of former Athenahealth CEO, Jonathan Bush | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Almost three years ago exactly, Jonathan Bush was forced out as CEO of Athenahealth—a company tha... |
| 16.06.2021 | Elanco Announces Agreement to Acquire Kindred Biosciences | |
| 02.06.2021 | Kindred Biosciences Announces Positive Results from Pivotal Efficacy Study of Parvovirus Monoclonal Antibody for the Prevention of Deaths in Dogs Infected by Parvovirus | |
| 11.05.2021 | KINDRED BIOSCIENCES, INC. Kindred Biosciences : Announces First Quarter 2021 Financial Results | SAN FRANCISCO, May 11, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2021... |
| 11.05.2021 | Kindred Biosciences Announces First Quarter 2021 Financial Results | |
| 28.04.2021 | Kindred Biosciences Announces Acceptance of Parvovirus Antibody Prophylaxis Study Data and Approval of Efficacy Indication | |
| 28.04.2021 | ELANCO ANIMAL HEALTH INCORPORATED Elanco Animal Health Incorporated : Kindred Biosciences Announces Acceptance of Parvovirus Antibody Prophylaxis Study Data and Approval of Efficacy Indication | SAN FRANCISCO, April 28, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the United States Department of Agriculture (USDA) Ce... |
| 16.03.2021 | Kindred Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results |
Show more